tirzepatide cardiovascular outcomes 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major events (12.2% vs 13.1%; HR 0.92). What Tirzepatide vs Dulaglutide for Cardiovascular

Our support team in Mandeville is fully equipped to handle insurance verification and the entire prior authorization process, allowing you to concentrate on your health and well-being

Exenatide and the treatment of patients with Parkinson's disease

#PsoriaticArthritis #GLP1 #Dermatology #Rheumatology #MedicalResearch GLP-1 therapy shows promise in psoriatic arthritis treatment A major new clinical trial is putting a spotlight on one of the biggest conversations in medicine right now: what happens when GLP-1based therapy is brought into psoriatic arthritis care

This suggests that GLP-1 receptor activation may primarily promote resolution mechanisms rather than directly suppressing initial inflammatory responses in the CNS